title: Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients.
abstract: BACKGROUND
  Hyperglycemia and insulin resistance frequently occur in critically ill and in morbidly obese (MO) patients. Both conditions are associated with altered serum levels of cytokines and adipokines. In addition, obesity related alterations in adipokine expression contribute to insulin resistance in metabolic syndrome. In this study we examined the serum adipocytokine profile in critically ill patients, MO patients, and healthy blood donors.
  
  
  METHODS
  33 patients who fulfilled the clinical criteria for severe sepsis or septic shock (SP) were prospectively enrolled in this study. A multiplex analysis was performed to evaluate plasma levels of adiponectin, resistin, leptin, active PAI-1, MCP-1, IL-1 alpha, IL-6, IL-8, IL-10, and TNF-alpha in 33 critically ill patients, 37 MO patients and 60 healthy blood donors (BD).
  
  
  RESULTS
  In SP, adiponectin was significantly lowered and resistin, active PAI-1, MCP-1, IL-1 alpha, IL-6, IL-8, IL-10, and TNF-alpha were significantly elevated compared to BD. Leptin levels were unchanged. In MO, adiponectin and IL-8 were significantly lowered, leptin, active PAI-1, MCP-1, IL-1 alpha, IL-6, and IL-10 significantly elevated, whereas resistin was unaltered. In SP, adiponectin correlated negatively with BMI, SAPS II and SOFA scores, while resistin correlated positively with SAPS II and SOFA scores and leptin correlated positively with the BMI. Adiponectin was approximately equally diminished in SP and MO compared to BD. With the exception of active PAI-1, cytokine levels in SP were clearly higher compared to MO.
  
  
  CONCLUSIONS
  A comparable adipocytokine profile was determined in critically ill and MO patients. As in MO, SP showed reduced adiponectin levels and elevated MCP-1, active PAI-1, IL-1 alpha, IL-6, and IL-10 levels. Leptin is only elevated in MO, while resistin, IL-8, and TNF-alpha is only elevated in SP. As in MO patients, increased levels of proinflammatory cytokines and altered levels of adipokines may contribute to the development of insulin resistance in critically ill patients.
authors.affiliation: Department of General-, Visceral-, and Transplantation Surgery, University Hospital of Ulm, Steinhoevelstr, Ulm, Germany. Andreas.Hillenbrand@uniklinik-ulm.de
authors.forename: Andreas
authors.initials: A
authors.lastname: Hillenbrand
authors.forename: Uwe
authors.initials: U
authors.lastname: Knippschild
authors.forename: Manfred
authors.initials: M
authors.lastname: Weiss
authors.forename: Hubert
authors.initials: H
authors.lastname: Schrezenmeier
authors.forename: Doris
authors.initials: D
authors.lastname: Henne-Bruns
authors.forename: Markus
authors.initials: M
authors.lastname: Huber-Lang
authors.forename: Anna M
authors.initials: AM
authors.lastname: Wolf
mesh_terms: D054392:Adipokines / Q000097:blood*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000097:blood*; D018805:Sepsis / Q000097:blood*
chemical_list: D054392:Adipokines; D016207:Cytokines
references.citation: Chest. 2000 Aug;118(2):503-8
references.pmid: 10936147
references.citation: Diabetes. 2002 Oct;51(10):2968-74
references.pmid: 12351435
references.citation: Blood. 2000 Sep 1;96(5):1723-32
references.pmid: 10961870
references.citation: Science. 1995 Jul 28;269(5223):543-6
references.pmid: 7624777
references.citation: Physiol Res. 2001;50(6):589-94
references.pmid: 11829320
references.citation: Biochem Biophys Res Commun. 2005 Sep 9;334(4):1092-101
references.pmid: 16039994
references.citation: Crit Care. 2009;13(4):R112
references.pmid: 19589139
references.citation: J Clin Invest. 1995 May;95(5):2409-15
references.pmid: 7738205
references.citation: Biochem Biophys Res Commun. 2003 Jan 10;300(2):472-6
references.pmid: 12504108
references.citation: Semin Cell Dev Biol. 1999 Feb;10(1):19-29
references.pmid: 10355025
references.citation: Chest. 2000 Apr;117(4):1162-72
references.pmid: 10767254
references.citation: J Clin Endocrinol Metab. 2001 May;86(5):1930-5
references.pmid: 11344187
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6735-41
references.pmid: 18980965
references.citation: Crit Care. 2009;13(3):R95
references.pmid: 19545363
references.citation: Curr Pharm Des. 2008;14(19):1887-99
references.pmid: 18691100
references.citation: Scand J Infect Dis. 2003;35(9):535-44
references.pmid: 14620132
references.citation: J Biol Chem. 2003 Nov 14;278(46):45777-84
references.pmid: 12952969
references.citation: Physiol Res. 2004;53(2):123-9
references.pmid: 15046547
references.citation: Pathophysiology. 2008 Aug;15(2):123-34
references.pmid: 18586471
references.citation: J Clin Endocrinol Metab. 2006 Nov;91(11):4620-7
references.pmid: 16895955
references.citation: J Pediatr (Rio J). 2007 Nov;83(5 Suppl):S192-203
references.pmid: 17989837
references.citation: Crit Care. 2009;13(4):R105
references.pmid: 19570238
references.citation: PLoS One. 2006 Dec 20;1:e31
references.pmid: 17183659
references.citation: Lancet. 1974 Jul 13;2(7872):81-4
references.pmid: 4136544
references.citation: FASEB J. 2008 Jun;22(6):2012-22
references.pmid: 18218920
references.citation: Diabetes. 1994 Nov;43(11):1271-8
references.pmid: 7926300
references.citation: Lancet. 2003 Jan 18;361(9353):226-8
references.pmid: 12547549
references.citation: N Engl J Med. 2006 Feb 2;354(5):449-61
references.pmid: 16452557
references.citation: Crit Care Clin. 2002 Jul;18(3):509-28
references.pmid: 12140911
references.citation: N Engl J Med. 1999 Jan 14;340(2):115-26
references.pmid: 9887164
references.citation: FEBS Lett. 2002 Oct 23;530(1-3):158-62
references.pmid: 12387885
references.citation: Am J Physiol Endocrinol Metab. 2001 May;280(5):E745-51
references.pmid: 11287357
references.citation: J Clin Endocrinol Metab. 1997 Dec;82(12):4196-200
references.pmid: 9398739
references.citation: Chest. 1992 Jun;101(6):1644-55
references.pmid: 1303622
references.citation: Trends Endocrinol Metab. 2002 Jan-Feb;13(1):18-23
references.pmid: 11750858
references.citation: J Interferon Cytokine Res. 2009 Jun;29(6):313-26
references.pmid: 19441883
references.citation: J Neuroendocrinol. 2008 Jan;20(1):120-7
references.pmid: 18081560
references.citation: Curr Opin Pharmacol. 2009 Aug;9(4):447-53
references.pmid: 19481975
references.citation: J Clin Endocrinol Metab. 1999 Jul;84(7):2438-42
references.pmid: 10404818
references.citation: JAMA. 1993 Dec 22-29;270(24):2957-63
references.pmid: 8254858
references.citation: Obesity (Silver Spring). 2006 Dec;14(12):2177-83
references.pmid: 17189544
references.citation: J Clin Endocrinol Metab. 1998 Jan;83(1):280-3
references.pmid: 9435456
references.citation: Circ J. 2010 Feb;74(2):213-20
references.pmid: 20065609
references.citation: Diabetes. 2007 Apr;56(4):1010-3
references.pmid: 17287468
references.citation: Biochem Biophys Res Commun. 2004 Apr 9;316(3):924-9
references.pmid: 15033490
references.citation: Endocrinology. 2004 May;145(5):2273-82
references.pmid: 14726444
references.citation: Crit Care Med. 2007 Jun;35(6):1536-42
references.pmid: 17452927